ARTICLE | Distillery Therapeutics
Cancer
May 23, 2017 8:32 PM UTC
Mouse studies suggest inhibiting FCGR2B and FCGR3 on macrophages could enhance effects of anti-PD-1 antibodies on tumors. In a xenograft mouse model of colorectal cancer treated with an anti-PD-1 anti...
BCIQ Company Profiles